| 
			
			 In addition, the research team reports in The New England Journal of 
			Medicine, "women were more likely to have breast cancer that was 
			overdiagnosed than to have earlier detection of a tumor that was 
			destined to become large." 
 “This new article will not change our guidelines,” said Dr. Richard 
			Wender, chief cancer control officer at the American Cancer Society, 
			who was not involved in the new research. It is simply showing a 
			trend, which is "the weakest form of evidence," he said.
 
 The American Cancer Society’s guidelines call for women to consider 
			having a mammogram at age 40, to actually have one each year 
			beginning at age 45 and then, at age 55, to consider having one 
			every other year. Wender said other medical groups have made similar 
			recommendations.
 
 The chief author of the new study, Dr. Gilbert Welch of the 
			Dartmouth Institute for Health Policy and Clinical Research in 
			Hanover, New Hampshire, and his coauthors found that mammography 
			resulted in the discovery of 162 more cases of breast cancer for 
			every 100,000 women, but only 30 of those small tumors were expected 
			to grow and become a danger.
 
			
			 
			That suggests more than four times as many cases - 132 in all - were 
			what is known as overdiagnosed.
 "Everyone should understand that there are tradeoffs in screening. 
			It's not a simple it-can-only-help-you kind of story," he told 
			Reuters Health.
 
 "If you have a new breast lump you should have a mammogram. There's 
			no doubt about that," he said. But otherwise, "women should 
			understand it's a choice."
 
 The debate is part of ongoing discussion about the effectiveness and 
			timing of breast cancer screening, whether better detection 
			technologies are identifying cancers that don't really pose a 
			threat, and how to treat the abnormalities that are found.
 
 "We've always been trained to think that the best test is the one 
			that finds the most cancer," Welch said. "That's way too easy. The 
			question is, who can find the cancers that matter? Who can help sort 
			out what cancers are really important?"
 
 Women who get breast cancer screening already have to deal with 
			false positives and paying for evaluations that may not be covered 
			by insurance, writes Dr. Joann Elmore in an accompanying editorial. 
			Now it's becoming clear that screening is causing overdiagnosis of 
			diseases that would never cause symptoms or death, she continues.
 
 "We need better methods of distinguishing biologically self-limited 
			tumors from harmful tumors that progress," writes Elmore, a 
			professor of medicine at the University of Washington School of 
			Medicine in Seattle.
 
 Wender disputes the conclusion in the new research that improved 
			treatment, and not mammography, is responsible for the decline in 
			breast cancer deaths.
 
			
            [to top of second column] | 
 
			Other studies have shown that breast screening cuts the death rate, 
			he said. In addition, in Denmark, which embraced screening 10 years 
			later than most Western countries, a decline in breast cancer deaths 
			was delayed by a decade.
 The data in the new study came from the U.S. national Surveillance, 
			Epidemiology, and End Results (SEER) program.
 
 Over the period from 1975 to 2012, mammograms did shift the balance 
			in how big tumors were when they were first discovered, researchers 
			found.
 
 The proportion of large tumors (that is, at least 2 cm in diameter) 
			went from 64 percent to 32 percent. Over time, smaller tumors became 
			the norm, representing 36 percent of the cancers at the start of the 
			study period and 68 percent by the end.
 
			Welch’s team writes that the modest decrease in the number of large 
			tumors detected over time "suggests that screening has had the 
			desired effect of advancing the time of diagnosis of some tumors 
			that were destined to become large.” At the same time, a much larger 
			increase in the incidence of small tumors suggests that screening 
			has led to women being “considerably more likely to have tumors that 
			were overdiagnosed than to have earlier detection of a tumor that 
			was destined to become large."
 The researchers estimate that at least two thirds of the reduction 
			in deaths may be due to better treatment. But the results presume 
			that the risk of developing breast cancer has not increased over 
			time.
 
			
			 
			
 "Virtually every other expert group has concluded that, in fact, the 
			incidence of breast cancer has been increasing," which would shift 
			the benefit in favor of mammography, Wender noted.
 
 SOURCE: http://bit.ly/2dYFQmL New England Journal of Medicine, 
			online October 12, 2016.
 
			[© 2016 Thomson Reuters. All rights 
				reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published, 
			broadcast, rewritten or redistributed. |